




- Oral, soluble guanylate cyclase (sGC) activator
- Potently and selectively activates the heme-free form of sGC *in vivo* and *in vitro*
- Currently in phase 2 clinical studies for treatment of chronic kidney disease and nonproliferative diabetic retinopathy
- First therapeutic principle targeting a key enzyme affected by persistent oxidative stress
- Can restore the pivotal but dysfunctional NO/sGC/cGMP signaling under oxidative stress



Hahn, M. G. *J. Med. Chem.* 2021. <https://doi.org/10.1021/acs.jmedchem.0c02154>

